CTAP

Research use only, not for human use.

Potent and selective μ opioid receptor antagonist (IC50 = 3.5 nM). Displays > 1200-fold selectivity over δ opioid and somatostatin receptors. Brain penetrant and active in vivo.

Potent and selective μ opioid receptor antagonist (IC50 = 3.5 nM). Displays > 1200-fold selectivity over δ opioid and somatostatin receptors. Brain penetrant and active in vivo.

——

CTAP (0-1 mg/kg, IP, single) blocks morphine’s antinociceptive effect.CTAP (10 mg/kg; IP, single) has no effect on L-DOPA-induced limb, axial, orolingual, or locomotor abnormal involuntary movements.CTAP is stable in the blood and serum of rats (T1/2 > 500 min), showing that the structure of this peptide offers enzymatic resistance. CTAP is extensively protein-bound to albumin in the perfusion medium (68.2%) and to proteins in rat serum (84.2%). Animal Model:Male Sprague-Dawley rats Dosage:0, 0.1, 0.5, 1 mg/kg Administration:IP, singleResult:Completely blocked morphine’s antinociceptive effect at 0.5 or 1 mg/kg.

——

Endocrinology/Hormones

Opioid Receptor

——

——

——

103429-32-9

1104.32

C51H69N13O11S2

>98% (HPLC)

water:1 mg/mL

[H]N[C@H](CC1=CC=CC=C1)C(=O)N[C@H]1CSSC(C)(C)C(NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC1=O)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O

——

(-20℃)

With Ice Pack

≥ 2 years